Foley Hoag Represents Organogenesis Holdings in $64.7M Follow-On Offering

December 1, 2020

Foley Hoag LLP represented leading regenerative medicine company Organogenesis Holdings Inc. (Nasdaq: ORGO) in the closing of its underwritten public offering of 19,916,708 shares of Class A common stock worth approximately $64.7 million in gross proceeds. Organogenesis Holdings intends to use the net proceeds from this offering, together with other available funds, for working capital and general corporate purposes, including, but not limited to, facility expansion and manufacturing enhancements, salesforce expansion and to conduct clinical studies of, obtain regulatory approvals and additional commercial insurance coverage for its products.

Organogenesis Holdings, located in Canton, Massachusetts, offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. The company’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.

The Foley Hoag team consisted of Stacie Aarestad, William Kolb, Ryan Rourke Reed, Caroline Samp, Anna Snook, Alissa Clarke, Nicholas Romanos, Philip Choi and Joshua Jarvis

About Foley Hoag LLP

Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.